0001104659-17-041012.txt : 20170622 0001104659-17-041012.hdr.sgml : 20170622 20170622194141 ACCESSION NUMBER: 0001104659-17-041012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170620 FILED AS OF DATE: 20170622 DATE AS OF CHANGE: 20170622 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001481512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262908274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 401-4060 MAIL ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lettmann Jason CENTRAL INDEX KEY: 0001688269 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37926 FILM NUMBER: 17926118 MAIL ADDRESS: STREET 1: C/O RA PHARMACEUTICALS, INC. STREET 2: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 a4.xml 4 X0306 4 2017-06-20 0 0001481512 Ra Pharmaceuticals, Inc. RARX 0001688269 Lettmann Jason C/O MORGENTHALER VENTURE PARTNERS IX, LP 3200 ALPINE ROAD PORTOLA VALLEY CA 94028 1 0 1 0 Options to Purchase Common Stock 22.37 2017-06-20 4 A 0 15000 0 A 2027-06-20 Common Stock 15000 15000 D On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option. /s/ Benjamin Piper, Attorney-in-Fact 2017-06-22